(Albany, US) DelveInsight has launched a new report on Muscle Invasive Bladder cancer Market
DelveInsight’s “ Muscle Invasive Bladder cancer Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Muscle Invasive Bladder cancer, historical and forecasted epidemiology as well as the Muscle Invasive Bladder cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Muscle Invasive Bladder cancer market report provides current treatment practices, emerging drugs, Muscle Invasive Bladder cancer market share of the individual therapies, current and forecasted Muscle Invasive Bladder cancer market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Muscle Invasive Bladder cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Bladder neoplasms can arise from any of the four bladder wall layers. They are broadly classified as either epithelial or non-epithelial (mesenchymal), with over 95% being epithelial. Epithelial tumors with differentiation toward normal urothelium are urothelial/ urinary carcinoma (UC). Other types of bladder neoplasms, namely, squamous cell carcinoma, adenocarcinoma, small cell carcinoma and sarcoma account for 2–5% of bladder neoplasms. The majority of UC occurs in males with approximately has two-to-three fold greater incidence as compared to females. UC is the invasion of the basement membrane or lamina propria by neoplastic cells of urothelial origin. The main causative agents of upper tract UC and urinary bladder cancer include cigarette smoking and work-related exposure, while other factors are more specific to the carcinogenesis of upper tract UC (i.e., Balkan endemic nephropathy).
Request for free sample page:- https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Several treatment protocols used for MIBC or Urothelial Carcinoma include chemotherapy, immunotherapy, radiation therapy, target specific therapy, and surgical treatment.
Metastatic Urothelial carcinoma has shown poor survival when treated with chemotherapy; however, due to the advancement in the treatment of new immunotherapies, more alternatives are available. Chemotherapy majorly forms the first line of treatment mainly comprising platinum-based products. Cisplatin-based chemotherapy is a chief product in the list of chemotherapeutics. The commonly used cisplatin regimens include MVAC (methotrexate, vinblastine, doxorubicin, cisplatin) or GC (gemcitabine and cisplatin). Cisplatin is followed by Carboplatin for therapeutic regimens, such as M-CAVI (methotrexate, carboplatin, and vinblastine). Few nonplatinum regimens include gemcitabine with a taxane (either paclitaxel or docetaxel) rather than platinum. Single-agent chemotherapy also holds importance in the treatment routine, including Gemcitabine, Vinflunine, and Ifosfamide.
The major class for treatment also comprise Immunotherapy that helps the patient’s own immune system to recognize and destroy cancer cells. Developments in this domain have led to the development of immune checkpoint inhibitors (ICIs) targeting programmed death (PD-1/PDL-1) pathway. Immunotherapy is used in platinum ineligible or refractory cases. The market holds Atezolizumab (Tecentriq), Pembrolizumab (Keytruda), Nivolumab (Opdivo), Durvalumab (Imfinzi), and Avelumab (Bavencio) as approved products targeting PD-1/PDL-1 pathway.
The Muscle Invasive Bladder cancer market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Muscle Invasive Bladder cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of Muscle Invasive Bladder cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, Muscle Invasive Bladder cancer market in 7MM is expected to change in the study period 2017-2030.
Muscle Invasive Bladder Cancer Report Scope
- The report covers the descriptive overview of Muscle Invasive Bladder cancer, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Muscle Invasive Bladder cancer epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Muscle Invasive Bladder cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of Muscle Invasive Bladder cancer market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Muscle Invasive Bladder cancer market
Download free sample page:- https://www.delveinsight.com/sample-request/muscle-invasive-bladder-cancer-market
Table of content
1. Key Insights
2. Executive Summary of Muscle Invasive Bladder cancer
3. Competitive Intelligence Analysis for Muscle Invasive Bladder cancer
4. Muscle Invasive Bladder cancer: Market Overview at a Glance
5. Muscle Invasive Bladder cancer: Disease Background and Overview
6. Patient Journey
7. Muscle Invasive Bladder cancer Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Muscle Invasive Bladder cancer Treatment
11. Marketed Products
12. Emerging Therapies
13. Muscle Invasive Bladder cancer: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Muscle Invasive Bladder cancer
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Muscle Invasive Bladder cancer market
- To understand the future market competition in the Muscle Invasive Bladder cancer market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Muscle Invasive Bladder cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Muscle Invasive Bladder cancer market
- To understand the future market competition in the Muscle Invasive Bladder cancer market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions